These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17214336)

  • 1. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
    He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
    Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thymidine kinase 1 activity in breast cancer.
    Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
    Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
    He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
    Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
    Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
    Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
    He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
    Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can thymidine kinase levels in breast tumors predict disease recurrence?
    O'Neill KL; Hoper M; Odling-Smee GW
    J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
    Wang Z; Zhang W; Huo B; Dong L; Zhang J
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
    Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
    Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.
    Huang ZH; Tian XS; Li R; Wang XM; Wen W; Guan H; Yang YJ
    Exp Ther Med; 2012 Feb; 3(2):331-335. PubMed ID: 22969891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
    Tribukait B
    BMC Cancer; 2020 May; 20(1):440. PubMed ID: 32423477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
    Wu C; Yang R; Zhou J; Bao S; Zou L; Zhang P; Mao Y; Wu J; He Q
    J Immunol Methods; 2003 Jun; 277(1-2):157-69. PubMed ID: 12799048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast tumour thymidine kinase levels and disease recurrence.
    O'Neill KL; McKelvey VJ; Hoper M; Monteverde H; Odling-Smee GW; Logan H; Abram WP; McKenna PG
    Med Lab Sci; 1992 Dec; 49(4):244-7. PubMed ID: 1339926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
    Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
    Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
    Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
    Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.